Amylyx initiated with bullish view at Deutsche Bank, here’s why

Deutsche Bank initiated coverage of Amylyx with a Buy rating and $36 price target. Lead product AMX0035 is currently sold in the U.S. with the brand name Relyvrio and Canada under brand name Albrioza for amyotrophic lateral sclerosis, or ALS, the analyst noted. Relyvrio’s U.S. launch has been “very impressive thus far,” the analyst added.